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Toxic epidermal necrolysis (TEN) and Stevens-Johnson syndrome (SJS) are severe skin reactions characterised by epider-
mal necrolysis. Skin reactions develop as a result of drug induced keratinocyte apoptosis. Certain drugs, like nonsteroidal 
anti-inflammatory agents, antimicrobial substances and anticonvulsants, cause TEN or SJS more frequently. We present the 
case of a fatal adverse cutaneous reaction after linezolid administration in a 66-year old patient with severe staphylococcal 
pneumonia during treatment in the intensive care unit. According to data from the National Agency for Medicinal Products 
and Medical Devices of Croatia (HALMED), TEN is a rare, but not an unexpected, side effect of this antimicrobial drug. Time 
of occurrence, distribution and the extent of skin lesions are not typical of TEN, but the result of the postmortal skin biopsy 
clearly indicates the cause of the reaction.
DUBRAVKA IVIĆ (  ) •
JOSIP IVIĆ •
GORDANA DOŠEN
Department of Anaesthesiology 
Reanimatology and Intensive Care Medicine
University Hospital Centre Osijek





Department of Pathology 
and Forensic Medicine
University Hospital Centre, Osijek, Croatia
DUBRAVKA IVIĆ • KSENIJA MARJANOVIĆ • JOSIP IVIĆ • 
GORDANA DOŠEN
CASE REPORT
   SIGNA VITAE 2014; 9(2): 65 - 67
Key words: epidermal necrolysis, 
toxic, linezolid, drug-related side 
effects and adverse reaction
Introduction
Toxic epidermal necrolysis (TEN) and 
Stevens-Johnson syndrome (SJS) are 
severe skin reactions characterized by 
epidermal necrosis. Mucous membra-
nes of the respiratory, digestive and 
urogenital systems can also be affec-
ted by necrolysis. Assumingly, a skin 
reaction develops as a result of drug 
induced keratinocyte apoptosis in over 
80% of all cases. Skin changes appear 
with a latency of a few days or weeks 
from administration of the causative 
agent. Certain drugs like nonsteroidal 
anti-inflammatory agents, antimicro-
bial substances and anticonvulsants 
cause TEN or SJS more frequently. 
Among chemically related substances 
a cross reaction is possible. Treatment 
outcomes depend on the patient’s pre-
morbid condition and the percentage of 
affected skin surface. Death as an out-
come is possible in 30% of all patients. 
(1-4) We present a case of fatal adver-
se cutaneous reaction after linezolid 
administration in a patient with severe 
staphylococcal pneumonia during trea-
tment in the intensive care unit.
Case presentation
A 66-year-old patient was admitted to 
our intensive care unit (ICU) following 
after an urgent craniotomy for a sponta-
neous hypertensive cerebral haemato-
ma (preoperative Glasgow Coma Score 
10).  His medical history showed that he 
had chronic obstructive pulmonary dise-
ase (COPD) and psoriasis, a penicillin 
allergy, and was also a smoker and a 
chronic alcoholic. Preoperative micro-
biological analysis of tracheal aspirate 
showed colonization with methicillin resi-
stant Staphylococcus aureus (MRSA). 
In the early postoperative period, the 
patient was conscious, with normal 
breathing and diuresis. An infectious 
complication developed during the 7th 
postoperative day, which aggravated 
the patient’s clinical condition. Treatment 
with vancomycin and meropenem was 
started, due to the suspicion of posto-
perative meningitis. The latter was not 
confirmed, but massive bilateral pneu-
monia was later established. MRSA and 
Acinetobacter baummani were isolated 
from tracheal aspirate. Despite appro-
priate antimicrobial therapy, the patient’s 
condition did not improve, clinical and 
laboratory parameters indicated sepsis 
with initial signs of organ dysfunction 
(hypotension, azotaemia, deterioration 
of respiratory function). MRSA was isola-
ted repeatedly from the tracheal aspirate. 
After three weeks of unsuccessful admi-
nistration of vancomycin, linezolid was 
introduced. Six hours after the first dose 
(600 mg), a purpuric eruption appe-
ared on the extensor surface of both 
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arms and legs. These petechial lesions 
were considered a manifestation of sep-
sis. After the second dose of linezolid, 
numerous confluent purpuric macules, 
bullae and erosions appeared in place 
of the earlier petechial eruption. These 
changes affected about 10% of the body 
surface area. The patient’s general con-
dition deteriorated dramatically, with cli-
nical signs of progressive organ failure 
(circulatory shock, anuria, deep coma). 
Due to suspicion that the skin lesions 
were related to linezolid treatment, it was 
omitted from further therapy. Despite the 
intensive therapeutic measures (mec-
hanical ventilation, vasoactive support, 
haemodialysis) the patient died three 
days later. Family members opposed 
autopsy, so it was not performed, but a 
postmortal skin biopsy was approved. 
The result of the skin biopsy suggested 
toxic epidermal necrolysis (figure 1). 
The incident was reported to the Natio-
nal Agency for Medicinal Products and 
Medical Devices of Croatia (HALMED) 
as a possible side effect of linezolid.
Discussion
The very short latency from line-
zolid administration to skin eruption 
and the distribution of the skin chan-
ges in our patient are not typical of 
TEN or SJS. These changes resem-
bled the appearance caused by vas-
culitis or erythema multiforme. (1-3) 
No consideration was given to the 
mucous membrane changes, nor was 
an autopsy performed which could 
have shown noticeable internal organ 
changes characteristic of epidermo-
lytic   syndrome. Skin biopsy results 
exclude the possibility of vasculitis or 
staphylococcus scaled skin syndrome, 
and refers to TEN or rather SJS (figure 
1). (3,4) A prominent deterioration of 
the patients’ clinical condition after the 
second drug dose was administered 
raised doubts about linezolid possibly 
being the cause, or at least the contribu-
ting factor, of the severe skin reaction. 
According to the HALMED report, TEN 
is not an unexpected and unintended 
effect of linezolid and can occur in 0.01 
to 0.1% of cases. It should be noted that 
the patient was simultaneously treated 
with several other drugs which could 
potentially cause TEN or SJS, including 
meropenem, vancomycin and esome-
prazole. However, he had been trea-
ted with these drugs previously without 
appearance of any cutaneous reaction. 
Vancomycin was excluded just before 
the linezolid introduction. The latter was 
omitted from further therapy after the 
clinical deterioration, and administra-
tion of meropenem and esomeprazo-
le was continued. It is not possible to 
exclude one of the stated drugs as the 
cause of the adverse reaction, which 
was clinically evident immediately after 
linezolid inclusion, or even the possibi-
lity of cross sensitivity to those drugs. It 
is presumed that in this case linezolid 
could have caused or triggered TEN, 
but the patient’s premorbid condition 
(psoriasis, allergic diathesis, infection) 
could have contributed to the occu-
rrence and the fatal outcome of the skin 
reaction. (5) 
Figure 1a.  Confluent necrosis of epidermis with subepidermal bulla and lymp-
hocytic and hystiocytic infiltration within the dermis (HE, 200X). 
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